Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
Aptar’s Intranasal Delivery System Utilized in Phase II Clinical Study of SPONTAN® Nasal Spray Supporting advancement of complex intranasal therapies through clinical development CRYSTAL LAKE, Ill., March 16, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dos